The retail sector continued its upward trend of Zhongbai Group for 10 days and 7 boards, and the retail sector continued its upward trend. Zhongbai Group for 10 days and 7 boards, Maoye Commercial and Actually Zhijia had daily limit, and Guangbai shares, Dashang shares, Central Shopping Mall and Hongqi Chain opened higher collectively.The main contract of the container transport index (European line) rose by 150.2 points in the day, and now it is reported at 2567.8 points, an increase of 6.21%.The negative spread of 10-year treasury bonds between China and the United States has expanded to more than 250BP, the largest since June 2002.
Southern Power Grid: In November, the installed capacity of industrial and commercial distributed photovoltaic projects was newly put into operation, with more than 500 MW. Southern Power Grid (003035) said at the institutional investor strategy meeting on December 12 that in 2024, the company will continue to give full play to the advantages of distributed photovoltaic energy-saving track, focusing on key industries with good industry prospects, strong sustainable operation ability and large electricity consumption, and increase development efforts. According to preliminary statistics, from January to November 2024, the installed capacity of industrial and commercial distributed photovoltaic projects was newly put into operation with more than 500 MW.Guojin Securities: The warm wind of medical policy comes first, then the progress of innovation going out to sea, and then the opportunity of performance reversal. Guojin Securities Research Report said that the core investment opportunities in the pharmaceutical sector in 25 years will revolve around three logics: 1) innovation going out to sea; 2) demand recovery; 3) Policy expectation reversal. At present, the policy warm wind comes first (the medical track policy continues to warm up, and the overall industry expectation is expected to be optimistic); Then, R&D and innovation will go to sea (innovative drug track will continue to make progress, and it will still be the hottest track in the pharmaceutical sector in 2025, especially it is recommended to pay attention to the clinical data reading and commercialization progress of the first-line target, as well as the fluctuation opportunity of the expected difference of the second-line innovative drugs), and then the performance growth rate is expected to bottom out in the first half of 2025 (but it will take time for this improvement in performance growth rate to come. Considering the current industry communication and historical base, it is expected that 4Q24 and 1Q25 should still be cautiously optimistic.)The central parity of RMB against the US dollar was reported at 7.1876, down by 22 points; The median price of the previous trading day was 7.1854, the official closing price of the previous trading day was 7.2630, and it closed at 7.2700 last night.
Chief Cabinet Secretary of Japan: Short-term data show that enterprises have a strong willingness to invest.In the exchange market, the national debt rose the most, with "National Debt 2404" rising more than 4%, "National Debt 23", "Special Country 24 03" and "Special Country 24 01" rising nearly 1%.Treasury bond futures opened, with 30-year main contracts rising by 0.48%, 10-year main contracts rising by 0.36%, 5-year main contracts rising by 0.25% and 2-year main contracts rising by 0.05%.